Kymera Therapeutics Reports Q1 2026 Results, Secures $45M Gilead Milestone, and Gains Two Fast Track Designations

summarizeSummary

Kymera Therapeutics reported increased Q1 2026 revenue, secured a $45 million milestone from Gilead for a licensed asset, and received two Fast Track designations for its lead immunology program, extending its cash runway into 2029.

check_boxKey Events

• Strong Q1 2026 Collaboration Revenue Growth

  Collaboration revenue increased by 55.5% year-over-year to $34.365 million in Q1 2026, primarily from the Gilead Agreement, compared to $22.100 million in Q1 2025 from the Sanofi Agreement.

• Gilead Exercises Option for KT-200, Triggers $45M Milestone

  In April 2026, Gilead Sciences, Inc. exercised its option to exclusively license KT-200, a CDK2 molecular glue degrader, resulting in a $45 million milestone payment expected in Q2 2026.

• Two Fast Track Designations for KT-621

  Kymera received Fast Track Designation for KT-621 for atopic dermatitis in December 2025 and for moderate to severe asthma in April 2026, potentially accelerating its development and regulatory review.

• Robust Cash Runway into 2029

  The company reported cash, cash equivalents, and marketable securities of $1,546 million as of March 31, 2026, which is expected to fund operations into 2029.

auto_awesomeAnalysis

Kymera Therapeutics reported a significant 55.5% year-over-year increase in collaboration revenue for Q1 2026, primarily driven by its partnership with Gilead. The company also announced a $45 million milestone payment from Gilead in April 2026 for the exclusive license of KT-200, a CDK2 molecular glue degrader, signaling strong progress in its oncology pipeline. Furthermore, Kymera received two Fast Track Designations for its lead immunology asset, KT-621, for both atopic dermatitis and moderate to severe asthma, which could accelerate regulatory review. Despite an expected increase in net loss and operating expenses as a clinical-stage biotech, the company maintains a robust cash runway into 2029. The CEO and CFO adopted routine 10b5-1 trading plans, which are pre-scheduled and not indicative of immediate insider selling pressure.